相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-inflammatory effects of diet and caloric restriction in metabolic syndrome
L. Montefusco et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2021)
Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies
Yongbo Wang et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2020)
Effects of Type II Diabetes Mellitus on Tendon Homeostasis and Healing
Anne E. C. Nichols et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2020)
Metformin use reduced the overall risk of cancer in diabetic patients: A study based on the Korean NHIS-HEALS cohort
Ye-Seul Kim et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System
Gholamreza Daryabor et al.
FRONTIERS IN IMMUNOLOGY (2020)
Preventive Role of Diet Interventions and Dietary Factors in Type 2 Diabetes Mellitus: An Umbrella Review
Phung Lam Toi et al.
NUTRIENTS (2020)
Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials
Chu Lin et al.
ENDOCRINE (2020)
Burden of diabetes, hyperglycaemia in China from to 2016: Findings from the 1990 to 2016, global burden of disease study
M. Liu et al.
DIABETES & METABOLISM (2019)
Does the use of incretin-based medications increase the risk of cancer in patients with type-2 diabetes mellitus?
Igor Karp et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2019)
Sulfonylurea derivatives and cancer, friend or foe?
Anne M. Hendriks et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis
Christopher B. Chen et al.
BMC CANCER (2018)
Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial
Michael A. Nauck et al.
DIABETES CARE (2018)
Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: An observational population-based study
Massimo Vicentini et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer
Joshua W. Russo et al.
CANCER RESEARCH (2018)
Fasting blood glucose and risk of prostate cancer: A systematic review and meta-analysis of dose-response
A. Jayedi et al.
DIABETES & METABOLISM (2018)
Correlation of Adiponectin With Testosterone in Patients With and Without Type 2 Diabetes and Erectile Dysfunction
Moustafa A. Elsaied et al.
AMERICAN JOURNAL OF MENS HEALTH (2018)
Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer
Christel Haggstrom et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Adi J. Klil-Drori et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review
Yuehong Chen et al.
JOURNAL OF DIABETES (2017)
Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer
Wolfgang Rathmann et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study
C. B. Chen et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2017)
Association Between Changes in Thyroid Hormones and Incident Type 2 Diabetes: A Seven-Year Longitudinal Study
Ji Eun Jun et al.
THYROID (2017)
SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
Huilin Tang et al.
DIABETOLOGIA (2017)
Metformin and prostate cancer mortality: a meta-analysis
Konrad H. Stopsack et al.
CANCER CAUSES & CONTROL (2016)
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
C. Coyle et al.
ANNALS OF ONCOLOGY (2016)
Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes
Chen-Pin Wang et al.
CANCER PREVENTION RESEARCH (2016)
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
Gadi Shlomai et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes
Chin-Hsiao Tseng
Oncotarget (2016)
Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case-control study
Naomi Boxall et al.
BMJ OPEN DIABETES RESEARCH & CARE (2016)
Metformin in Cancer Treatment and Prevention
Daniel R. Morales et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study
Tom Feng et al.
CANCER PREVENTION RESEARCH (2015)
Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study
R. S. Weinstock et al.
DIABETES OBESITY & METABOLISM (2015)
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
B. Bode et al.
DIABETES OBESITY & METABOLISM (2015)
The risk of prostate cancer for men on aspirin, statin or antidiabetic medications
Tobias Nordstrom et al.
EUROPEAN JOURNAL OF CANCER (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Functional expression of sodium-glucose transporters in cancer
Claudio Scafoglio et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis
A. D. Raval et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44+CD117+ ovarian cancer stem cells
Rongrong Zhang et al.
STEM CELL RESEARCH & THERAPY (2015)
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
Konstantinos K. Tsilidis et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
Konstantinos K. Tsilidis et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Are Sulfonylurea and Insulin Therapies Associated With a Larger Risk of Cancer Than Metformin Therapy? A Retrospective Database Analysis
Bernd Kowall et al.
DIABETES CARE (2015)
Canaglif lozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
Lawrence A. Leiter et al.
DIABETES CARE (2015)
Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau)
Marco Randazzo et al.
WORLD JOURNAL OF UROLOGY (2015)
Reduced Risk of Lung Cancer With Metformin Therapy in Diabetic Patients: A Systematic Review and Meta-Analysis
Zhi-Jiang Zhang et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2014)
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
Jisun Kim et al.
BMC CANCER (2014)
Human Insulin Does Not Increase Prostate Cancer Risk in Taiwanese
Chin-Hsiao Tseng
CLINICAL GENITOURINARY CANCER (2014)
Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
Takashi Nomiyama et al.
DIABETES (2014)
Metformin Does Not Affect Cancer Risk: A Cohort Study in the UK Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial
Konstantinos K. Tsilidis et al.
DIABETES CARE (2014)
HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
Bo Ahren et al.
DIABETES CARE (2014)
Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus
Chin-Hsiao Tseng
EUROPEAN JOURNAL OF CANCER (2014)
Type 2 diabetes mellitus, glycemic control, and cancer risk
Adedayo A. Onitilo et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2014)
Metformin Use and Prostate Cancer Risk
Mark A. Preston et al.
EUROPEAN UROLOGY (2014)
Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09)
Christian Rothermundt et al.
EUROPEAN UROLOGY (2014)
Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer
Ido Laskov et al.
GYNECOLOGIC ONCOLOGY (2014)
Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study
H. C. Lin et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2014)
Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data
Kazuki Murai et al.
DRUGS IN R&D (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
A population-based cohort study in Taiwan-use of insulin sensitizers can decrease cancer risk in diabetic patients?
C. -H. Kao et al.
ANNALS OF ONCOLOGY (2013)
Metformin Use and All-Cause and Prostate Cancer-Specific Mortality Among Men With Diabetes
David Margel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-analysis using primary data of published studies
Bindiya Thakkar et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies
D. Bansal et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2013)
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies
Michael J. Pishvaian et al.
CANCER (2012)
The influence of antidiabetic medications on the development and progression of prostate cancer
Anna Hitron et al.
CANCER EPIDEMIOLOGY (2012)
Insulin use and cancer risk in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies
I. N. Colmers et al.
DIABETES & METABOLISM (2012)
Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea Derivatives Results from a large population-based follow-up study
Rikje Ruiter et al.
DIABETES CARE (2012)
Cancer occurrence in Danish diabetic patients: duration and insulin effects
B. Carstensen et al.
DIABETOLOGIA (2012)
The Influence of Type 2 Diabetes and Glucose-Lowering Therapies on Cancer Risk in the Taiwanese
Ming-Chia Hsieh et al.
EXPERIMENTAL DIABETES RESEARCH (2012)
Insulin-Like Growth Factors and Insulin: At the Crossroad Between Tumor Development and Longevity
Ruslan Novosyadlyy et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2012)
The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes
Marcus Lind et al.
PRIMARY CARE DIABETES (2012)
Systematic Review and Meta-analysis of Insulin Therapy and Risk of Cancer
Mohsen Janghorbani et al.
HORMONES & CANCER (2012)
Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients
X. -X. He et al.
ANNALS OF ONCOLOGY (2011)
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation
Emily Jane Gallagher et al.
YEAR IN DIABETES AND OBESITY (2011)
Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
Assiamira Ferrara et al.
DIABETES CARE (2011)
Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer A retrospective cohort study of older Medicare patients
Nancy E. Morden et al.
DIABETES CARE (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
Goodarz Danaei et al.
LANCET (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Diabetes and Cancer: A Consensus Report
Edward Giovannucci et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
P. D. Home et al.
DIABETOLOGIA (2010)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs
Toshikatsu Okumura
JOURNAL OF GASTROENTEROLOGY (2010)
PPARγ-independent antitumor effects of thiazolidinediones
Shuo Wei et al.
CANCER LETTERS (2009)
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
Irina N. Alimova et al.
CELL CYCLE (2009)
Additive Interaction Between the Renin-Angiotensin System and Lipid Metabolism for Cancer in Type 2 Diabetes
Xilin Yang et al.
DIABETES (2009)
New Users of Metformin Are at Low Risk of Incident Cancer A cohort study among people with type 2 diabetes
Gillian Libby et al.
DIABETES CARE (2009)
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
C. J. Currie et al.
DIABETOLOGIA (2009)
Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis
M. Marzioni et al.
GUT (2009)
Weight-loss outcomes: A systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up
Marion J. Franz et al.
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION (2007)
Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis
Marco Marzioni et al.
GASTROENTEROLOGY (2007)
Cancer risks in thiazolidinedione users compared to other anti-diabetic agents
Carol Koro et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Rangaswamy Govindarajan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Peroxisome proliferator-activated receptor γ-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation
Chih-Cheng Yang et al.
CANCER RESEARCH (2007)
Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications
C. M. Velicer et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2007)
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
Herbert Tilg et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Peroxisome proliferator-activated receptor γ-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells
CC Yang et al.
MOLECULAR PHARMACOLOGY (2006)
Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin
SL Bowker et al.
DIABETES CARE (2006)
Prostate cancer risk among men with diabetes mellitus (Spain)
A González-Pérez et al.
CANCER CAUSES & CONTROL (2005)
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms
A Galli et al.
GUT (2004)
分享论文
